NASH
08/2020

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

EASL International Liver Congress
Read More
NASH
07/2020

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Hepatology 2020
Read More
PRESS RELEASES
06/2020

Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640

Oral FASN inhibitor TVB-2640 significantly reduces liver fat with a 61% responder rate Demonstrates improvement in markers of liver function and fibrosis Results to be presented on August 28 at…
Read More
PRESS RELEASES
03/2020

Data on Sagimet’s Lead Candidate TVB-2640 to be Presented at EASL ILC 2020

Phase 2 (FASCINATE-1) clinical data in NASH accepted for late-breaker oral presentation; preclinical data accepted for poster presentation San Mateo, California, March 31, 2020 – Sagimet Biosciences, a clinical-stage biotechnology…
Read More
Uncategorized
09/2019

FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS-mutant NSCLC patients in a phase I study

(Poster Presentation at AACR Meeting on Monday Apr 18, 2016 1:00 PM, Abstract number LB-214)
Read More
Uncategorized
09/2019

3-V Biosciences to Present at the 2015 Wedbush PacGrow Healthcare Conference on August 12, 2015

Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, announced today that it will present at the 2015 Wedbush…
Read More
PRESS RELEASES
08/2019

3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing

Name connotes expertise in fatty acid metabolism and therapeutic focus targeting dysfunctional metabolic pathways  San Mateo, California, August 5, 2019 ­– 3-V Biosciences, a clinical-stage biotechnology company, announced today that…
Read More
Oncology
06/2019

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

ASCO
Read More
PRESS RELEASES
04/2019

3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH

San Mateo, California, United States, and Hangzhou and Shaoxing, China, 30 April 2019 – 3-V Biosciences, Inc. (3-V Biosciences) and Ascletis Pharma Inc. (Ascletis, 1672.HK) announced today that 3-V Biosciences…
Read More
PRESS RELEASES
02/2019

Ascletis and 3-V Biosciences Announce NASH Strategic License and Series E Financing

Hangzhou and Shaoxing, China and San Francisco, California, United States, 13 February 2019, Ascletis Pharma Inc. (Ascletis, 1672.HK) and 3-V Biosciences, Inc. (3-V Biosciences) jointly announce today that Ascletis, through its…
Read More